Advanced Cell Diagnostics, Inc. services

There is growing interest in RNA-based biomarkers and measuring RNA expression holds great promise for stratifying patients based on drug response, drug efficacy and risk of side effects. RNAscope in situ hybridization enables molecular detection in a morphological context. It provides the cellular resolution required to evaluate tissue heterogeneity and to potentially better screen and select patients.

Application of RNAscope™ ISH in our Good Clinical Laboratory Practices (GCLP) compliant Professional Assay Services laboratory.  RNAscope is the only assay that can specifically detection engineered cell therapies and measure target engagement in intact human tumor biopsies.

To accurately interpret gene expression in tissues, scientists are in need of a quantitative assay that provides spatial information at the molecular level. The RNAscope™, BaseScope™, and miRNAscope™ ISH technologies enable single molecule detection of RNAs in situ within the tissue context. Our highly trained scientific experts and pathologists offer various quantification methodologies. The analyses are defined according to the biological question being addressed, and each project is supported by consultations with the scientific team.

ACD has curated a collection of dozens of pre-sourced validated and un-validated tissue blocks, available to our PAS customers, to support the development of ISH probes and assays.

ACD`s Professional Assay Services group has been developing RNAscope™ biomarker assays for our biopharma partners for a decade. Our biomarker assays have contributed to important clinical trial exploratory endpoints, enabled more accurate patient selection, and are leading to CDx development with our partner, Leica Biosystems. Leveraging the unrivalled sensitivity and specificity of ACD’s ISH technologies, RNAscope or BaseScope biomarker assays can be developed for any therapeutic target, including those that are challenging for antibody detection such as many neo-antigens, cancer vaccine and TCR targets, as well as highly homologous gene families such as MAGEA. RNAscope, BaseScope(TM) and miRNAscope(TM) biomarker assays are typically more sensitive than IHC and often correlate better with response to treatment whereas less sensitive IHC assays report false-negative results.